Lantheus, GE finalize license agreement

By staff writers

April 25, 2017 -- Lantheus Holdings subsidiary Lantheus Medical Imaging has signed a definitive agreement with GE Healthcare to support the worldwide development and commercialization of its flurpiridaz F-18 investigational PET radiopharmaceutical. The firms are also continuing their current supply agreement for other nuclear medicine products.

Following on a term sheet the companies signed in February, the definitive agreement provides for GE to lead and fund the development program of flurpiridaz F-18, including a second phase III clinical study. In addition, GE will have exclusive worldwide rights to commercialize the radiopharmaceutical, a myocardial perfusion imaging (MPI) agent designed to improve the diagnosis of coronary artery disease.

Lantheus will collaborate in both the development and commercialization process through a joint steering committee, and the company also maintains the option to copromote the agent in the U.S. In return, Lantheus receives a $5 million cash payment and up to $60 million in regulatory and sales milestone payments. It will also receive double-digit royalties on U.S. sales and single-digit royalties on sales outside of the U.S, according to the companies.

In a separate development, Lantheus and GE have also extended and expanded their current commercial supply agreement for other nuclear medicine offerings. As a result, Lantheus will continue to supply GE with its TechneLite, gallium-67, and xenon-133 radiopharmaceuticals through December 31, 2020.

Report: GE targets 3D printing acquisitions
Industrial conglomerate GE is eyeing additional corporate acquisitions in 3D printing to complement deals it made in 2016, according to an April 20 article...
GE inks long-term relationship with Conn. health system
GE Healthcare has initiated a seven-year collaboration with Hartford HealthCare in Hartford, CT, focused on using analytics to achieve measurable improvements...
GE awarded HealthTrust purchasing deal
GE Healthcare will provide SPECT and PET radiopharmaceuticals to members of the HealthTrust group purchasing organization across the U.S.
Lantheus plans secondary offering of 3M shares
Lantheus Holdings said that certain of its existing stockholders will sell 3 million shares of its common stock in a public secondary offering.
Lantheus inks deal with GE for flurpiridaz PET tracer
Lantheus Medical Imaging has signed a term sheet with GE Healthcare to support the worldwide development and commercialization of its flurpiridaz F-18...
FDA clears updated Lantheus Definity label
The U.S. Food and Drug Administration (FDA) has approved a label update for Lantheus Medical Imaging's Definity ultrasound contrast agent.

Copyright © 2017